Skip to main content

Table 2 LASSO-selection of best predictors

From: Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus

Metabolite

Mean estimate

Standard deviation

95 % CI

Selection percentagea

Asymmetric dimethylarginine (ADMA)

4.4

6.5

0, 22

52.4

Asparagine (Asp)

−3.0

7.4

−26, 0

26.2

Carnitine (C0)

−2.4

6.8

−24, 0

20.0

Acylcarnitine (C12-DC)

11.3

24.6

0, 88

31.4

Linoleoylcarnitine (C18:2)

−3.0

7.5

−27, 0

22.8

Acylcarnitine (C5:1-DC)

2.9

7.4

0, 25

23.4

Glutarylcarnitine (C5-DC/C6-OH)

3.3

7.5

0, 28

27.2

Acylcarnitine (C6:1)

3.7

9.9

0, 34

23.5

Acylcarnitine (C7-DC)

2.39

6.99

0, 25

20.6

Octanoylcarnitine (C8)

−3.0

8.8

−31, 0

20.6

Citrulline (Cit)

−2.0

4.9

−17, 0

27.5

Glutamine (Gln)

3.7

7.8

0, 28

31.8

Histidine (His)

7.5

14.0

0, 48

36.2

Lysophosphatidylcholines (lysoPC a C16:0)

−10.4

18.4

−62, 0

36.9

Lysophosphatidylcholines (lysoPC a C16:1)

−2.9

6.4

−22, 0

26.2

Phosphatidylcholines (PC aa C36:0)

4.5

7.0

0, 23

44.1

Phosphatidylcholines (PC aa C42:2)

9.7

13.8

0, 46

51.6

Symmetric dimethylarginine (SDMA)

0.3

1.0

0, 3

22.5

Spermine

−3.9

7.0

−24, 0

36.2

Tryptophan (Trp)

6.2

12.2

0, 41

35.1

Valine (Val)

3.5

8. 7

0, 31

24.4

  1. Results from LASSO regression of 21 metabolites selected for the serum metabolites classifier, five fold cross-validation, and bootstrap resampling (N = 1000) in the discovery cohort of patients with type 2 diabetes with microalbuminuria (n = 49)
  2. aThe relative frequency of the marker being included in the model across 1000 bootstrap resamples